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Reason for the study: To standardize the use of flow cytometry for classifying hematological malignancies
and make the results reliable and reproducible across laboratories, the EuroFlow™ Consortium published a
comprehensive specification of antibody-fluorochrome conjugates, standard protocols, and algorithms for anal-
ysis. The BD OneFlow™ system builds on, and further standardizes, the EuroFlow protocols. We aimed to
assess the effects on safety, efficiency, and costs for laboratories of adopting the BD OneFlow reagent tubes
(LST and B-CLPD T1) for diagnosing chronic lymphocytic leukemia.
Methods: We compared in-house laboratory processes and results with those using the LST and B-CLPD T1
reagent tubes with, and without, blood film morphology. Outcome measures included concordance in classifi-
cation results, and efficiency within the laboratory, that is, resource usage, staff time, unwanted events, and
cost-consequences.
Results: There was 100% concordance between the classifications made with in-house flow cytometry and
those with the BD OneFlow reagent tubes. Using BD OneFlow tubes required 13 hours less staff time per month
(i.e. for 100 samples) than the in-house process. Sensitivity analyses explored the effects of uncertainties in
the price of the BD OneFlow tubes and the prevalence of CLL and identified the thresholds at which laboratories
might expect cost-savings from adopting the BD OneFlow system. Laboratory and clinical staff considered the
BD OneFlow system to be safe and effective.
Conclusions: Laboratories adopting the BD OneFlow system for classifying patients with suspected CLL can
expect safe, efficient processes that can be cost saving if the discount on the list price, and prevalence of CLL
(which will both vary between sites and countries), is within the thresholds suggested by the health economics
sensitivity analysis. © 2019 The Authors. Cytometry Part B: Clinical Cytometry published by Wiley Periodicals, Inc. on behalf of
International Clinical Cytometry Society.
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Recent advances in flow cytometric immuno-
phenotyping technologies allow suspected hematologi-
cal malignancies to be rapidly and accurately classified.
Many laboratories providing this service devise their
own antibody-fluorochrome combinations, develop,
and validate the testing panel in-house, and then ana-
lyze the diagnostic data accordingly. One result of this
nonstandardized approach is that, while a final diagno-
sis made by two different laboratories on the
same sample might not differ, there will be different
workflows and different data generated for analysis. In
2004, the EuroFlow Consortium initiated a project to
standardize the use of flow cytometry for the classifica-
tion of hematological malignancies and to make the
results reliable and reproducible across laboratories.
The outcome was a comprehensive specification of the
antibody-fluorochrome conjugates, standard protocols,
and algorithms for analysis (1).
BD Biosciences have developed a system, BD
OneFlow™, which builds on, and further standardizes,
the EuroFlow specifications and protocols by providing
a set of reagent tubes with premixed dried-down anti-
bodies, new standard operating procedures for instru-
ment setup and compensation (calibration), acquisition,
and analysis templates. New software for multivariate
analysis, Infinicyt™ (Cytognos SL, Salamanca, Spain), is
available for EuroFlow databases (1–3). The initial two
reagent sets available from the planned full BD OneFlow
product line were the lymphoid screening tube (LST) and
the first of four reagent tubes for classifying B cell lym-
phoproliferative disorders, the B-cell Chronic Lympho-
proliferative Diseases Tube 1 (B-CLPD T1). The reagents
in these two tubes have been validated by EuroFlow for
the immunophenotyping of chronic lymphocytic leuke-
mia (CLL). CLL was selected as the condition of interest
for this study because it is the most common lympho-
proliferative disorder and constitutes the bulk of the
work in a clinical flow cytometry laboratory (4).
We hypothesized that adoption of the BD OneFlow
system would improve the efficiency of sample processing
in the laboratory (particularly in terms of staff time)
and reduce the occurrence of near misses (events such
as reagent mix-ups and sample labeling errors that
were detected before misclassification could occur).
This would reduce the risk of error, without any nega-
tive impact on the diagnostic service offered in terms of
diagnostic accuracy. The study therefore focused on
laboratory outcomes, without considering the impact of
diagnostic results on patients.
We compared classification with current in-house
practice to classification using the BD OneFlow LST
and B-CLPD T1 reagent tubes with, and without, periph-
eral blood film morphology. We assessed the contribu-
tion of blood film morphology to classification with
OneFlow, because centralized laboratories may not
have access to this.
METHODS AND MATERIALS
Methods for Workflow Evaluation
Setting. The study was carried out by the flow cyto-
metry service that is housed within the Blood Sciences
Laboratory of the Royal Victoria Infirmary (RVI),
Newcastle upon Tyne Hospitals NHS Foundation Trust
(NUTH). The laboratory is home to the Northern England
Haemato-Oncology Diagnostic Service (NEHODS).
Patient population. Samples were from adults with a
lymphocytosis. Patient would have been clinically
assessed to exclude infectious causes of lymphocytosis,
so the prevalence of CLL was expected to be high,
around 50%. Referrals came from general practitioners
(GPs), NUTH clinics and hospitals, and other laborato-
ries and hospitals.
Study design. This was a prospective observational
cohort study in which three testing and classification
strategies were followed for each sample:
1. Current practice: Flow cytometry using in-house
antibody/fluorochrome cocktails and full blood count
data, other routinely used diagnostic information, and
peripheral blood film morphology. This information
was used to make the final diagnosis and guide clinical
decisions.
2. BD OneFlow with morphology: Flow cytometry
using the BD OneFlow LST and B-CLPD T1 reagent
tubes, full blood count data, other routinely used diag-
nostic information, and blood film morphology. This is
potentially an immediate efficiency improvement possi-
ble within current NHS practice.
3. BD OneFlow without morphology: Flow cyto-
metry using the BD OneFlow tubes, full blood count
data, and other routinely used diagnostic information,
but excluding morphology. This is potentially a novel
(in the NHS) and even more efficient practice that
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might be suitable for regional/national service laborato-
ries if it can be shown to be accurate.
No information from the BD OneFlow flow cytometry
was made available to the patient or to their clinicians.
Classification of flow cytometry results. We chose
to study CLL as it is the most common B cell malig-
nancy seen in our laboratory. The study used simplified
versions of the clinical classification (4) and the long-
standing flow cytometry CLL “Matutes score” (5) so that
we could compare the efficiency of the BD OneFlow
LST tube with the in-house process. The efficiency ana-
lyses used both a minimal and a more fine-grained clas-
sification as follows:
1. Samples were first classified as CLL; or Another con-
dition; or Indeterminate—following the Matutes
score. Indeterminate is a clonal B cell condition with
some features of CLL, but not all.
2. Then the non-CLL samples were subclassified as
Malignant (i.e. any other clonal lymphoid disorder)
or nonmalignant. Samples with CLL phenotype (clonal
B-lymphocyte count <5 × 109/L) were included with
nonmalignant cases for the concordance and health
economics analyses.
Concordance. Results were classified as concordant
or discordant according to whether classification with
the BD OneFlow reagent tubes (Strategies 2 and 3) was
the same as, or different from, classification with the in-
house laboratory procedure (Strategy 1).
We took account of three causes for discordance:
design, interpretation, and inaccuracy.
Discordant by design. While the in-house process
and the process with the BD OneFlow LST and B-
CLPD T1 reagent tubes are both designed to classify
samples as CLL or non-CLL, their designs differ in the
further classification that is possible, in particular the
ability to classify T cell disorders as likely malignant
or not—our in house strategy cannot classify T cell dis-
orders. For the purposes of this study, immuno-
phenotyping that differed between strategies because
of differences in further classification were reviewed
by an expert panel, where appropriate regarded as
“discordant by design,” counted as concordant in
terms of diagnosis of CLL and are reported separately.
Discordant by interpretation. The results of the
BD OneFlow immunophenotyping for classification
with and without peripheral blood film morphology
were interpreted by different hematologists. When
interpretations differed, this was regarded as “discor-
dant by interpretation” and the difference resolved
(if possible) by expert panel review.
Discordant by inaccuracy. If immunophenotyping
differed for reasons other than design or interpretation,
this was regarded as discordance by inaccuracy.
Efficiency outcome measures. The key value prop-
osition for the BD OneFlow system, increased effi-
ciency within the laboratory, was assessed in terms of
(1) resource usage (e.g. consumables such as anti-
bodies and other reagents; validation of new batches of
reagents; maintenance contracts); (2) staff time
(e.g. instrument setup and calibration; stock manage-
ment, steps in preparation for and processing of samples;
analysis and reporting of flow cytometry results; train-
ing); (3) untoward events (e.g. errors in preparation of
test cocktails; expiry of unused stock); and (4) health
economics: cost-consequences and budget impact.
Sample size and recruitment considerations.
Approximately 100 flow cytometry tests for CLL are car-
ried out routinely in the laboratory each month. It was
estimated that, over a study period of 4 months, 100 sam-
ples could be enrolled and processed, and that generaliz-
able conclusions on efficiency could be drawn from the
data. For future studies on accuracy and utility, the data
can be used to estimate optimal sample sizes.
Data management and statistical analysis. Data
from the collection forms were entered into a spread-
sheet, which was used to calculate the classification
performance statistics.
Methods for Multicolor Flow Cytometric Immunophenotyping
Peripheral blood samples were processed by two dif-
ferent techniques: in-house and BD OneFlow methods.
In-house method. The in-house method follows
the process recommended by the British Committee
for Standards in Hematology or validated against their
guidelines (6). Whole blood was diluted, if required,
to a white cell count of <20 × 109/L in phosphate buff-
ered saline (PBS). Blood for the kappa/lambda tube
only was washed three times in PBS. Blood was then
stained for immunophenotyping using the in-house four
tube antibody panel, each tube containing four or five
colors as detailed in Table 1. The concentrations of these
antibodies were determined with standard titration stud-
ies. After 15 min incubation, the samples were lysed
with BD FACS™ lysing solution (Becton Dickinson,
BD). After a further 15 min incubation, tubes were cen-
trifuged once and the cell pellet resuspended in PBS. In-
house panels were acquired within 1 h of staining using
BD FACSDiva™ software in-house templates, and
10,000 lymphocyte events, as defined by a forward-side
scatter gate, were collected. Experiment application set-
tings were derived from BD™ CS&T beads and BD™
CompBeads (catalogue numbers 656,047 and 552,843).
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Beads are fluorescent particles, used to set photo-
multiplier voltages so that fluorescence levels are opti-
mized. Analysis was carried out using in-house BD
FACSDiva software templates.
Samples found not to have a clonal B cell population
were set up with the BD Multitest™ 6-color TBNK
reagent, which detects T, B, and natural killer (NK) cells.
BD OneFlow method. The antibody panels for the
LST and B-CLPD T1 reagent tubes are detailed in
Table 1. The tubes and specimens were processed
according to the manufacturer’s instructions (7,8). BD
OneFlow tubes were acquired immediately after speci-
men staining on a BD FACSCanto™ II, equipped with
three lasers, using BD FACSDiva software and BD One-
Flow acquisition templates, and 100,000 events were
collected. Instrument settings were derived from the
BD OneFlow Setup beads and the BD FC beads, 8-color
kit for BD OneFlow (catalogue number 658620). Analy-
sis was carried out using BD FACSDiva analysis tem-
plates specifically designed for BD OneFlow
application. Statistics were edited to allow for the mean
fluorescence intensity for kappa, lambda, CD20, and
CD79b to be accessed. The process was evaluated on a
normal population before the project started.
Ethics and research governance. This study was
approved by the HRA (IRAS project ID 196260, REC
reference 16/NE/0369). The study sponsor was the
Newcastle upon Tyne Hospitals NHS Foundation Trust,
(R&D approval reference 8059).
Methods for Health Economic Evaluation
The health economics methods are described in the
Supporting Information section.
RESULTS
Concordance Analysis
One hundred samples were obtained between March
13, 2017 and July 27, 2017; 56 patients had CLL;
44 patients had other causes of lymphocytosis, 27 of
which were nonmalignant and 17 malignant. Nine sam-
ples were CLL phenotype and (for analysis only) are
included with the nonmalignant group. Although the
protocol specified that patients who had previously
been diagnosed with CLL would be excluded, data from
six such samples (inadvertently enrolled) were retained
for the analyses, because their removal would have
made no significant difference to the conclusions, and
the full data set more precisely represents the usual
flow cytometry workload for CLL investigation.
Classification with BD OneFlow immunophenotyping
was as accurate as with the in-house laboratory procedure.
There were two instances of “discordant by design” in
which BD OneFlow identified B cells that the in-house lab-
oratory process was not sensitive enough to detect, and
these are shown in Figures 1 and 2. There was a single
instance of initial “discordant by interpretation,” which
on review, was regarded concordant for distinguishing
between CLL and non-CLL. Accurate classifications using
the BD OneFlow LST and B-CLPD T1 tubes were made
without blood film morphology in all 100 cases. For
details on concordance, see Table S3 in the online
Table 1
Antibody Panels Used with In-House Testing and with BD OneFlow LST and B-CLPD T1 Tubes
Fluorochromes FITC PE Per-CP-Cy 5.5 PE-Cy 7 APC APC-H7 V450 V500
In-house panels
Lymph one Antibody FMC7 CD23 CD19 CD5
Clone FMC7 EBV CS-5 SJ2 5C1 L17F12
Lymph two Antibody CD103 CD22 CD20 CD10 CD45
Clone Ber-ACT8 S-HCL-1 L27 HI10a 2D1
Lymph three Antibody CD79b CD38 CD19 CD11c
Clone SN8 HB-7 SJ2
5C1
S-HCL-3
Lymph four Antibody CD2 anti-lambda CD19 anti-kappa
Clone S5.2 1-155-2 SJ2 5C1 TB 28–2
Fluorochromes FITC PE PerCP-Cy 5.5 PE-Cy 7 APC APC-Cy7
6 –ColorTBNK Antibody CD3 CD16 CD45 CD4 CD19 CD8
Clone SK7 B73.1 2D1 SK3 SJ25C1 SK1
Antibody CD56
Clone NCAM16.2
BD OneFlow antibody panels
Fluorochromes FITC PE PerCP-Cy 5.5 PE-Cy 7 APC APC-H7 V450 V500
BD OneFlow LST Antibody CD8 CD56 CD5 CD19 CD3 CD38 CD4 CD45
Clone SK1 MY31 L1F12 SJ25-C1 SK7 HB7 SK3 2D1
Antibody anti-lambda anti-kappa CD20
Clone 1–155-2 TB28 L27
BD OneFlow B-CLPD Antibody CD23 CD10 CD79b CD19 CD200 CD43 CD20 CD45
Clone EBV CS-5 MEM-78 SN8 SJ25-C1 MRC OX-104 1G10 L27 2D1
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Supporting Information. Because the study did not aim to
evaluate diagnostic performance and safety, it was not
powered to do so, and no P-values were calculated.
Efficiency Outcomes: Staff Time and Laboratory
Consumables
No unwanted events such as running out of stock
or errors in processing were observed with either the
BD OneFlow or the in-house approaches. However,
laboratory staff thought that the likelihood of such
unwanted events would be lower with the BD OneFlow
system, because there are fewer reagent tubes to man-
age, fewer reagents to process, no manual reagent
pipetting, longer shelf-life, and reagents can be stored
at room temperature rather than in a refrigerator.
Resource usage and costs for the three testing
strategies are detailed in Supporting Information
FIG. 1. The difference in information provided by the in-house and BD OneFlow processes (discordance by design) is illustrated by plots (a) and (b).
Plot (a), for in-house tube four, gated on FSC V SCC, shows that B cell events are low and the population in the north-east quadrant is not distinct. Plot
(b), for the LST reagent tube gated on B cells, shows the abnormal blue population much more clearly than is possible with the in-house process.
FIG. 2. The difference in information provided by the in-house and BD OneFlow processes (discordance by design) is illustrated by the two pairs of
plots. Plot (a) shows in-house reagent tube 1 and Plot (b) in-house reagent tube 4; both plots are gated on FSC V SSC. A large CD5+ kappa restricted B
cell population is clearly visible. Plots (c) and (d) are for the BD OneFlow LST tube gated on B cells. A second, small, lambda restricted CD5+ B cell
population is visible on plot (c) and in plot (d), but is not clear in the in-house tubes.
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Tables S2–S13. Of the 100 samples, 21 could be classi-
fied on the LST tube results alone, and 79 required the
B-CLPD T1 tube to complete the CLL/non-CLL classifi-
cations; 25 samples that did not have a clonal B cell
population were also tested with the TBNK tube to fur-
ther classify the non-CLL group.
Using BD OneFlow tubes required 13 hours less per
month (i.e. for 100 samples) than the in-house process,
with the greatest time saving coming from pipetting
and preparing tubes. Details are listed in the Supporting
Information Table S2 and visualized in Figure 3. The
staff estimated that further time savings of around
30 hours per month would have been possible if the
Infinicyt software had been used. The health economics
analyses took into account the pay band (salary level) of
the different kinds of staff required for each task that was
timed, and details are shown in the Supporting Informa-
tion Tables S2, S3, and S4. With blood film morphology
being done in all cases, there would be a saving of
£36.63 per sample (£3663 per month), if all samples
could be classified with the BD OneFlow LST tube alone.
There would be an additional cost of £21.61 per sample
(£2161 per month) were classification to also require the
B-CLPD T1 tube—see Supporting Information Table S7.
Full details of the budget impacts are given in the
Supporting Information Table S13.
Exploration of the Effects of Uncertainties in Input
Parameters
Sensitivity analyses explored the effects on the results
due to uncertainties in the model’s input parameters.
FIG. 3. Differences in staff time per specimen which would follow from adopting the BD OneFlow system (with blood film morphology). Processes that
would take the same time are not shown. Time savings are associated with a cost saving. Further cost savings arise when lower salary grade staff can be
employed. These potential cost savings are not shown in the figure but are detailed in the tables.
FIG. 4. This bivariate sensitivity analysis shows the effect on costs of (i) case-mix (the prevalence of CLL in samples, i.e. the proportion of cases which
require the B-CLPD T1 reagent tube after testing with the LST tube) and (ii) the discount on the list price of LST and B-CLPD T1 reagent tubes. The
plots assume that the cost of blood film morphology is included. As this is both small and constant, lines for costs excluding blood film morphology are
not shown.
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Supporting Information Table S12 shows the sensitivity
analysis that explores the impact that changes in the
proportion of cases which require both the LST and B-
CLPD T1 reagent tubes would have on costs compared
to current practice. When LST alone is sufficient for CLL
classification in 40% of cases (with both LST and B-
CLPD T1 used in the remaining 60%), the expected cost
of testing with BD OneFlow is less than the expected
cost of testing with current practice (which assumes that
the B-cell panel is always required, with no TBNK). Cost
savings of BD OneFlow increase further as this percent-
age is increased.
Figure 4, an additional sensitivity analysis, is an aid
to applying these findings to other sites and countries.
Savings depend on the new laboratory’s costs for CLL
classification (which include costs of staff time and use
of resources), the laboratory’s discount on BD OneFlow
list prices, and their case-mix, that is, the proportion of
cases being investigated for CLL which require both the
BD OneFlow LST and the B-CLPD-1 reagent tubes. The
x-axis crosses the y-axis at £0, that is, changes in costs
are zero if the new site has the same costs as our study
site. To apply the plot in Figure 4 to another site, draw
a line parallel to x-axis so that it crosses the y-axis at
the difference between the cost for current methods at
the study site and at the new site—in effect this is
changing the reference or base cost to reflect that of
the prospective new site. Identify the point on the new
line where it crosses the line that represents the case-
mix at the new site. The X-value of this point estimates
the discount on the BD OneFlow list prices at which
savings could be realized by the new laboratory.
DISCUSSION
The BD OneFlow system proved safe and capable of
generating savings in the context of a regional labora-
tory in the UK NHS. With the use of the sensitivity ana-
lyses that explored the effects of uncertainties in the
model’s input parameters, the results can be applied to
other sites in other countries. Efficiencies in terms of
staff time saved by adopting the BD OneFlow system
were assessed in terms of person-hours and costs of
person-hours when taking pay scales into account.
However, this undervalues the benefits of standardiza-
tion with BD OneFlow, because this approach omits,
for example, the impact on the operation of the labora-
tory when a flow cytometer is occupied for more than
an hour with setup and validation processes that need
to be carried out at regular intervals. The value of the
additional information provided by the BD OneFlow
system is illustrated by two patients who had abnormal
B cell populations that were detected with the BD One-
Flow LST tube but not with the in-house method. Their
immunophenotyping is shown in Figures 1 and 2.
Laboratory and clinical staff identified a range of pros
and cons for the BD OneFlow system compared to
the in-house processes. Pros include standardization
(which assures quality and safety, reduces the need for
operator training, and supports the laboratory’s accredi-
tation) and the inclusion of anti-CD200 in the antibody
panel, which allows separation of mantle cell lym-
phoma from other B cell disorders (9). Possible cons
(which would be site-specific) include cost, the need
for three lasers in the flow cytometer, and the need for
training for clinicians interpreting the results.
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